CTRI Number |
CTRI/2023/02/049929 [Registered on: 21/02/2023] Trial Registered Prospectively |
Last Modified On: |
21/02/2023 |
Post Graduate Thesis |
No |
Type of Trial |
PMS |
Type of Study
|
Ayurveda Nutraceutical |
Study Design |
Single Arm Study |
Public Title of Study
|
To check the effect of Migraine -XS tablet in patients having Migraine |
Scientific Title of Study
|
An open label single arm clinical study to evaluate the efficacy of Migraine-XS tablet in Migraine |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
MGCTS/20/114 version1.0 dated 27August 2022 |
Protocol Number |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Rakhi Mehra |
Designation |
Principal Investigator |
Affiliation |
Shree Ram Hospital |
Address |
Dept of General Medicine, Room-8, Ground Floor, Shree Ram Hospital, NH-58, Delhi - Haridwar Highway, Partapur Bypass Rd, Meerut
Meerut UTTAR PRADESH 250103 India |
Phone |
7015579562 |
Fax |
|
Email |
raakhimehra49@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Puneet Mittal |
Designation |
Clinical Research Consultant |
Affiliation |
Mittal Global Clinical Trial Services |
Address |
Dept of Clinical Research, First Floor, MGCTS Building, Mansarovar Ind Estate, Panchli Khurd, Baghpat Road
Meerut UTTAR PRADESH 250002 India |
Phone |
8937045757 |
Fax |
|
Email |
puneetmittal@mgcts.org |
|
Details of Contact Person Public Query
|
Name |
Puneet Mittal |
Designation |
Clinical Research Consultant |
Affiliation |
Mittal Global Clinical Trial Services |
Address |
Dept of Clinical Research, First Floor, MGCTS Building, Mansarovar Ind Estate, Panchli Khurd, Baghpat Road
Meerut UTTAR PRADESH 250002 India |
Phone |
8937045757 |
Fax |
|
Email |
puneetmittal@mgcts.org |
|
Source of Monetary or Material Support
|
Mittal Ayurved Sansthan, Sant Vihar, T. P. Nagar, Meerut |
|
Primary Sponsor
|
Name |
M Global Nutraceuticals |
Address |
A Mittal Ayurved Sansthan Company, 121-B, Mansarovar Industrial Estate, Panchli Khurd, Baghpat Road, Meerut, India |
Type of Sponsor |
Pharmaceutical industry-Indian |
|
Details of Secondary Sponsor
|
Name |
Address |
Not Applicable |
Not Applicable |
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Rakhi Mehra |
Shree Ram Hospital |
Dept of General Medecine, Room-8, Ground Floor, Shree Ram Hospital, NH-58, Delhi-haridwar highway, Partapur Byepass rd, Meerut Meerut UTTAR PRADESH |
7906672912
raakhimehra49@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
SRAMCH Institutional Ethics Committee |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition:G439||Migraine, unspecified. Ayurveda Condition: ARDHAVABEDAKAH, |
|
Intervention / Comparator Agent
|
sno | Intervention/Comparator | Type | Drug-Type | Procedure Name | Details | 1 | Intervention Arm | Drug | Other than Classical | | (1) Medicine Name: Migraine XS Tablets, Reference: NA, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/Tablets, Dose: 1000(mg), Frequency: bd, Bhaishajya Kal: Adhobhakta, Duration: 1 Months, anupAna/sahapAna: No, Additional Information: - |
|
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
65.00 Year(s) |
Gender |
Both |
Details |
1.Subjects of either sex
2.Age 18-65 years (both inclusive)
3.People who have severe pain at half portion of their head.
4.If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study.
5.Are able to give written informed consent in a manner approved by the Institutional Ethics Committee and comply with the requirements of the study.
6.Are willing to avoid participation in any other interventional clinical trial for the duration of this study.
7.Are willing to refrain from using any lotions, gel, balm, other than those issued as part of the study, on the treatment areas during the treatment period.
|
|
ExclusionCriteria |
Details |
1.Are pregnant, breast-feeding, or planning to become pregnant during the study.
2.Cluster headache patients(its different from migraine)
3.Have participated in any interventional clinical trial in the previous 30 days.
4.Have a known sensitivity to any of the constituents of the test products .
5.Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.
|
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Case Record Numbers |
Blinding/Masking
|
Open Label |
Primary Outcome
|
Outcome |
TimePoints |
Change in the Subject Global Assessment |
day 0 and Day 30 |
|
Secondary Outcome
|
Outcome |
TimePoints |
change in pain (0-4) |
day 0 and Day 30 |
Change in Migraine Severity scores (MIGSEV) |
day 0 and Day 30 |
Change in Migraine Disability Assessment(MIDAS) score |
day 0 and Day 30 |
|
Target Sample Size
|
Total Sample Size="37" Sample Size from India="37"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
Post Marketing Surveillance |
Date of First Enrollment (India)
|
25/02/2023 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="0" Months="6" Days="0" |
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
Recruitment Status of Trial (India) |
Open to Recruitment |
Publication Details
|
Nil |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
|
Migraine is a spectrum disease, usually manifesting as an episodic or chronic primary headache disorder, characterized by attacks that can last from a few hours to up to three days. It is two to three times more prevalent among women than men, and women experience higher levels of pain, longer lasting attacks, and greater disability than men. For much of the twentieth century, migraine’s causes were considered to be vascular, and the pain a result of dilation of the cranial blood vessels. Since the 1970s, the emphasis has shifted, and it is now defined as a disorder involving nerve pathways and chemicals in the brain, to which people are often genetically predisposed. While migraine is still understood to affect the neurovascular system, it seems likely that the headache pain comes from neurogenic inflammation, rather than vasodilation. This is a problem of brain function, rather than structure. As the website for the National Migraine Centre in London explains, “if the brain is a computer, migraine is a software not a hardware problem.†Nevertheless, a huge amount remains unknown, including the role of the hypothalamus (the part of the brain that controls the endocrine system and has a role in the menstrual cycle, pain modulation, and governance of the body’s circadian rhythms), the cause of premonitory symptoms, the extent to which antimigraine drugs can access the brain, and the role of the blood-brain barrier. |